How do you approach selection of dose and fractionation for definitive treatment of localized skin cancers?

I presume the question applies to non melanoma skin cancers, i.e. basal cell or squamous. These lesions were frequently treated with RT years ago before the advent of Mohs surgical techniques but are now seldom seen in RT departments. Too bad, because in my experience, relatively short courses of RT...

Consider more fractionated radiotherapy for larger target volumes and patients with longer life expectancy and potential for late sequelae of treatment.